Croissy-Beaubourg, March 30, 2022, 7:30 a.m. CEST – THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in the in vitro diagnosis of autoimmune diseases and Theranostics, announces today that a change in the composition of its Board of Directors will be submitted to the vote at the Annual General Meeting of May 5, 2022.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]